We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Glucose Point-of-Care Measurements Evaluated for Gestational Diabetes

By LabMedica International staff writers
Posted on 04 Mar 2020
Gestational diabetes is a condition in which a woman without diabetes develops high blood sugar levels during pregnancy. More...
Gestational diabetes generally results in few symptoms; however, it does increase the risk of pre-eclampsia, depression, and requiring a Caesarean section.

Glucose meter devices are not currently recommended for diagnostic purposes. An important factor to consider is that almost all of the prior studies evaluating the diagnostic capability of point-of-care (POC) measurement for gestational diabetes mellitus (GDM) compare the POC results with venous glucose samples as the reference standard with suboptimal sample handling.

Scientists from the Coombe Women and Infants University Hospital (Dublin, Ireland) recruited 202 women who agreed to participate were followed up with an oral glucose tolerance test (OGTT) (mean gestation, 27.5 ±1.0 weeks) after an overnight fast (≥8 hours) between October 2017 and November 2018. A 2-hour 75 g OGTT was conducted to screen for GDM. The team collected venous samples in a sodium fluoride additive tube the Sarstedt Fluoride EDTA S-Monovette (Sarstedt AG & Co., Nümbrecht, Germany) with immediate placement on an ice-water slurry for transportation to the laboratory within 30 minutes for prompt centrifugation to prevent glycolysis.

Glucose was measured by the hexokinase method using a Beckman Coulter AU640 analyzer (Brea, CA, USA) with a CV percentage (CV%) of 2.0% at 103 mg/dL (5.7 mmol/L) and 234 mg/dL (13.0 mmol/L). The scientists collected a drop of capillary whole blood from a distal fingertip to measure POC capillary glucose using the Bayer Contour XT meter (Leverkusen, Germany). This meter uses a flavin adenine dinucleotide glucose dehydrogenase measuring system and was selected for its performance over a wide hematocrit range.

The scientists reported that the mean ±SD time between collection of the reference standard venous samples on ice-water slurry and transportation to the laboratory for centrifugation was 17 ± 9.7), 13 ± 9.0, and 13 ± 8.9 minutes for the fasting, 1-hour, and 2-hour samples, respectively, confirming adherence to international guidelines. Based on the plasma sample, the rate of GDM was 53.5% using the recent International Association of Diabetes and Pregnancy Study Groups criteria. The correlation between POC capillary and laboratory plasma glucose was greater than 0.9 at all three time points in the derivation cohort. As a predictor of GDM, the diagnostic accuracy of POC measurement was 83.0% (95% confidence interval, 74.2–89.8).

The authors concluded that in high-resource settings where measures to inhibit glycolysis are implemented, the use of POC measurements for the diagnosis of GDM is not justified based on this study. However, in low- and medium-resource settings, where measures to inhibit glycolysis are not practicable, regression analysis using POC measurements may be acceptable compared with plasma samples subject to glycolysis. The study was published in the February 2020 issue of the journal Clinical Chemistry.

Related Links:
Coombe Women and Infants University Hospital
Sarstedt AG & Co
Beckman Coulter
Bayer



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.